This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PA-1050040
Description: PA-040 is a second-generation maturation inhibitor and is expected to work by the same target as bevirimat. Bevirimat blocks HIV maturation by inhibiting the final step in the processing of the HIV Gag protein. The resulting virus particles are structurally defective and are incapable of spreading infection around the body.
In vitro studies with PA-040 have shown that the compound has a lower level of binding to human serum proteins than bevirimat, and thus the potential ability to have activity against HIV strains that exhibit partial bevirimat resistance. PA-040 retains wild-type activity against one of two bevirimat-resistant HIV isolates that represent the most-frequently mutated amino acids found by in vitro resistance-selection experiments performed to date.
Additional information available to subscribers only: